Neurogen Corporation Announces Executive Appointments to Vice President.BRANFORD, Conn. -- Neurogen Corporation (Nasdaq: NRGN NRGN Neurogen Corporation (Branford, Connecticut) ), a small molecule drug discovery and development company, announced today that it has appointed three executives to positions as vice president: Arunee Changchit, Vice President, Drug Metabolism Drug Metabolism/Interactions Definition Drug metabolism is the process by which the body breaks down and converts medication into active chemical substances. Precautions Drugs can interact with other drugs, foods, and beverages. and Pharmacokinetics; Jeffrey Dill, Vice President, General Counsel and Secretary; and Ricardo Ochoa, Vice President, Preclinical Safety. William H. Koster, Ph.D, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Neurogen said, "These appointments represent important steps as Neurogen continues to grow. In addition to our acknowledged accomplishments in drug discovery, we have expanded our capabilities in functional areas that are critical to a maturing organization, as we move our pipeline and the Company forward to build value for shareholders. Neurogen is extremely pleased to have executives of the caliber of Arunee, Jeff, and Ricardo on our team." Dr. Changchit leads the Drug Metabolism and Pharmacokinetics department at Neurogen, and is responsible for a full range of drug metabolism and pharmacokinetic studies in support of drug candidate selection and regulatory submissions. She reports to Dr. Stephen Uden, Executive Vice President and Head of R&D. She joined Neurogen in 1992 as Senior Scientist and assumed positions of increasing responsibility at the Company, to Director in 1998 and then to Senior Executive Director in 2004. She had previously served as Senior Research Pharmacokineticist at Marion Merrell Dow in Cincinnati and as Associate Professor of Forensic Medicine forensic medicine: see medical jurisprudence. forensic medicine Science of applying medical knowledge to legal questions, recognized as a specialty since the early 19th century. Its primary tool has always been the autopsy, to identify the dead (e.g. at Chulalongkorn University Medical School in Bangkok, Thailand. Dr. Changchit holds a B.S. degree in Pharmacy from Chiengmai University in Thailand, a PhD in Toxicology from the University of Kentucky The University of Kentucky, also referred to as UK, is a public, co-educational university located in Lexington, Kentucky. in Lexington, and a Doctor of Pharmacy America Canada In Canada the Pharm. D. programme is offered in both English and French. It has been available from the University of British Columbia since 1991 and at the University of Toronto, both offering it as a post-graduate degree. degree, also from the University of Kentucky. She also was a Clinical Pharmacology Fellow at the University of Colorado Health Sciences Center The University of Colorado Health Sciences Center (UCHSC) is part of the University of Colorado System. It has recently been merged with the University of Colorado at Denver (UCD) to form the University of Colorado at Denver and Health Sciences Center. in Denver. Mr. Dill has assumed responsibility for all legal affairs of the Company. In addition to his responsibilities as General Counsel, he is also responsible for the Intellectual Property, Facilities Management and Health, Environment, and Safety departments. He reports to Stephen Davis, Executive Vice President and Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. . He joined Neurogen in 2006 as Executive Director & Chief Corporate Counsel, having previously served as Vice President, Associate General Counsel at Premcor Inc. in Greenwich. Prior to Premcor, Mr. Dill had worked as in-house legal counsel in positions of increasing responsibility at ConocoPhillips Company. Mr. Dill earned his B.S. in Geology from West Virginia University West Virginia University, mainly at Morgantown; coeducational; land-grant and state supported; est. and opened 1867 as an agricultural college, renamed 1868. in Morgantown, his M.B.A. from California State University, Fullerton California State University, Fullerton, commonly known as CSUF, CSU Fullerton, or Cal State Fullerton, is a part of the California State University system. The University is located in the city of Fullerton, California, in northern Orange County. , and his J.D. from Western State University College of Law For the Colorado college, see . Western State University, College of Law (WSU) is a for-profit, American law school in Fullerton, California. It is the oldest law school in Orange County and boasts almost 10,000 alumni. in Fullerton, California. Dr. Ochoa is responsible for Drug Safety and Toxicology, ensuring that each of the Neurogen's drug programs is supported with the technical and strategic expertise to execute appropriate toxicology studies and to evaluate drug safety matters. He is also responsible for seeking appropriate enabling technologies and biomarker strategies that will enhance Neurogen's research and development capabilities. He reports to Dr. George Maynard who leads the Early Development Group. Dr. Ochoa joined Neurogen in 2006. Previously, he held positions of increasing responsibility at Pfizer Inc, most recently as Executive Director of Pathology, and was previously with The Upjohn Company where he served as Senior Research Veterinary Pathologist. He was also a professor in the School of Veterinary Medicine, Louisiana State University Louisiana State University and Agricultural and Mechanical College, generally known as Louisiana State University or LSU, is a public, coeducational university located in Baton Rouge, Louisiana and the main campus of the Louisiana State University System. . Dr. Ochoa holds a D.V.M. degree from Universidad Nacional de Colombia, Bogata, Columbia and a Ph.D. from Cornell University, New York State School of Veterinary Medicine, Pathology Department. He is board certified in Veterinary Pathology (ACVP ACVP American College of Veterinary Pathologists ACVP Authorized COMSEC Vendor Program ). About Neurogen Neurogen Corporation is a drug discovery and development company focusing on small molecule drugs to improve the lives of patients suffering from disorders with significant unmet medical need, including insomnia, Parkinson's disease and restless legs syndrome Restless Legs Syndrome Definition Restless legs syndrome (RLS) is characterized by unpleasant sensations in the limbs, usually the legs, that occur at rest or before sleep and are relieved by activity such as walking. (RLS Restless legs syndrome (RLS) A disorder in which the patient experiences crawling, aching, or other disagreeable sensations in the calves that can be relieved by movement. RLS is a frequent cause of difficulty falling asleep at night. ), pain, obesity, and depression. Neurogen conducts its research and development independently and, when advantageous, collaborates with world-class pharmaceutical companies to access additional resources and expertise. Safe Harbor Statement The information in this press release contains certain forward-looking statements, made pursuant to applicable securities laws that involve risks and uncertainties as detailed from time to time in Neurogen's SEC filings, including its most recent 10-K. Such forward-looking statements relate to events or developments that we expect or anticipate will occur in the future and include, but are not limited to, statements that are not historical facts relating to the timing and occurrence of anticipated clinical trials, and potential collaborations or extensions of existing collaborations. Actual results may differ materially from such forward-looking statements as a result of various factors, including, but not limited to, risks associated with the inherent uncertainty of drug research and development, difficulties or delays in development, testing, regulatory approval, production and marketing of any of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy or pharmacokinetic properties of the Company's drug candidates or other properties of drug candidates which could make them unattractive for commercialization, advancement of competitive products, dependence on corporate partners, the Company's ability to retain key employees, sufficiency of cash to fund the Company's planned operations and patent, product liability and third party reimbursement risks associated with the pharmaceutical industry. For such statements, Neurogen claims the protection of applicable laws. Future results may also differ from previously reported results. For example, positive results or safety and tolerability in one clinical study provides no assurance that this will be true in future studies. Neurogen disclaims any intent and does not assume any obligation to update these forward-looking statements, other than as may be required under applicable law. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion